Gene expression changes in a chemoresistant model with human esophageal cancer xenografts using cDNA microarray

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1163-1168

  Yoshida, Takahiro ^a   Miyoshi, Takanori ^a,b   Seike, Jun Ichi ^a   Yamai, Hiromichi ^a   Takechi, Hirokazu ^a   Yuasa, Yasuhiro ^a   Tangoku, Akira ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA PREFECTURAL CENTRAL HOSPITAL   (Japan)

Author keywords

Chemoresistance; Esophageal cancer; Microarray

Indexed keywords

CISPLATIN; COMPLEMENTARY DNA; FLUOROURACIL; PHOSPHATIDYLINOSITOL 3 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CONTROL GROUP; CONTROLLED STUDY; DISEASE SEVERITY; DNA MICROARRAY; ESOPHAGUS CANCER; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FLUOROURACIL; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 64949084216     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y and Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg 232: 225-232, 2000.
2. Enzinger PC, Ilson DH and Kelsen DP: Chemotherapy in esophageal cancer. Semin Oncol 26: 12-20, 1999.
3. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C and Wilke H: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310-2317, 2005.
4. Law S, Fok M, Chow S, Chu KM and Wong J: Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 114: 210-217, 1997.
5. Chan HS, Haddad G, Thomer PS, DeBoer G, Lin YP, Ondrusek N, Yeger H and Ling V: P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614, 1991.
6. Schneider S, Uchida K, Brabender J, Baldus SE, Yochim J, Danenberg KD, Salonga D, Chen P, Tsao-Wei D, Groshen S, Hoelscher AH, Schneider PM and Danenberg PV: Down- regulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 200: 336-344, 2005.
7. Saito T, Hikita M, Kohno K, Tanimura H, Miyahara M and Kobayashi M: Enhanced expression of the multidrug resistance gene in vindesine-resistant human esophageal cancer cells. Oncology 51: 440-445, 1994.
8. Miyoshi T, Kondo K, Ishikura H, Kinoshita H, Matsumori Y and Monden Y: SCID mouse lymphogenous metastatic model of human lung cancer constructed using orthotopic inoculation of cancer cells. Anticancer Res 20: 161-163, 2000.
9. Kondo K, Fujino H, Miyoshi T, Ishikura H, Sakiyama S and Monden Y: Orthotopically implanted SCID mouse model of human lung cancer suitable for investigating metastatic potential and anticancer drug effects. Oncol Rep 12: 991-999, 2004.
10. Fujino H, Kondo K, Miyoshi T, Ishikura H, Takahashi Y, Sawada N, Hirose Y, Takizawa H, Nagao T, Sakiyama S and Monden Y: Establishment of patient-like SCID mouse model by orthotopically implanting primary cultured cells from surgically- resected lung cancer tissues. Oncol Rep 10: 1709-1715, 2003.
11. Wada Y, Yoshida K, Suzuki T, Mizuiri H, Konishi K, Ukon K, Tanabe K, Sakata Y and Fukushima M: Synergistic effects of docetaxel and S-l by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119: 783-91,2006.
12. Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, Chan F, Gonzalez C, Zhang L and Samaha RR: Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics 7: 59, 2006.
13. Ingenuity ®RSystems, www.ingenuity.com
14. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO and Weinstein JN: A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236-244, 2000.
15. Suganuma K, Kubota T, Saikawa Y, Abe S, Otani Y, Furukawa T, Kumai K, Hasegawa H, Watanabe M, Kitajima M, Nakayama H and Okabe H: Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci 94: 355-9,2003.
16. Fujiwara H, Terashima M, Irinoda T, Takagane A, Abe K, Nakaya T, Yonezawa H, Oyama K, Takahashi M, Saito K, Takechi T, Fukushima M and Shirasaka T: Superior antitumour activity of S-l in tumours with a high dihydropyrimidine dehydrogenase activity. Eur J Cancer 39: 2387-2394, 2003.
17. Takechi T, Fujioka A, Matsushima E and Fukushima M: Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38: 1271-1277, 2002.
18. Takara K, Obata Y, Yoshikawa E, Kitada N, Sakaeda T, Ohnishi N and Yokoyama T: Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Cancer Chemother Pharmacol 58: 785-793, 2006.
19. Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL and Haber M: Expression of the gene for multidrug-resistance- associated protein and outcome in patients with neuroblastoma. N Engl J Med 334: 231-238, 1996.
20. Rubio-Viqueira B and Hidalgo M: Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 7: 501-512, 2006.